Breaking News Instant updates and real-time market news.

ABT

Abbott

, ALR

Alere

09:41
10/19/16
10/19
09:41
10/19/16
09:41

Abbott CEO says company 'not overindexed' to China

Abbott CEO Miles White said it is too early to issue a forecast for 2017, but he said that underlying growth across the business continues to be strong, outside of its nutrition business in China. Abbott is not "overindexed" to China, White added.

ABT

Abbott

ALR

Alere

  • 19

    Oct

  • 21

    Oct

  • 06

    Nov

ABT Abbott

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
ALR Alere

08/09/16
08/09/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 2. Chevron (CVX) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company offers "impressive financial resilience and dividend sustainability." 2. Alere (ALR) upgraded to Buy from Neutral at BTIG with analyst Dane Leone saying the 10-K helped to alleviate concerns that material deficiencies exist with the current financial model and is more comfortable with forecasts, and with the $56 price stated within the Abbott (ABT) merger agreement. 3. Buffalo Wild Wings (BWLD) upgraded to Neutral from Underperform at Credit Suisse with analyst Jason West saying the presence of activist investor Marcato could provide a "floor" for the stock and a be a win-win for shareholders. 4. Waste Management (WM) upgraded to Overweight from Sector Weight at KeyBanc with analyst Joe Box saying he believes volumes are undergoing a positive inflection point and that the company's price gains are sustainable. 5. Skyworks (SWKS) upgraded to Outperform from Underperform at CLSA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/24/16
PIPR
08/24/16
NO CHANGE
PIPR
Abbott, Alere likely to agree to reduced takeover price, says Piper Jaffray
Piper Jaffray analyst Alex Olvera believes that Abbott (ABT) is building evidence to bolster its case that Alere (ALR) has undergone a material adverse change since Abbott agreed to acquire it. However, the analyst says he thinks that Delaware, where any litigation between the companies would occur, has never ruled that a material adverse change has occurred in any other case. Consequently, Olvera says there is "a high probability" that the takeover price for Alere will be lowered by 10%-15%. There is a "medium probability" that the cash component of the offer will be reduced and replaced with stock or Contingent Value Rights, according to the analyst. Finally, there is a "low probability" of the merger being terminated, he wrote.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.

TODAY'S FREE FLY STORIES

COLD

Americold Realty Trust

20:35
01/18/18
01/18
20:35
01/18/18
20:35
Syndicate
Americold Realty Trust 45.3M share IPO priced at $16.00 »

The company sold 29M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

HTGM

HTG Molecular

$3.40

0.54 (18.88%)

20:29
01/18/18
01/18
20:29
01/18/18
20:29
Syndicate
HTG Molecular 12M share Secondary priced at $2.90 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

NINE

Nine Energy Services

20:27
01/18/18
01/18
20:27
01/18/18
20:27
Syndicate
Nine Energy Services 7M share IPO priced at $23.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

, STI

SunTrust

$67.94

-0.41 (-0.60%)

20:25
01/18/18
01/18
20:25
01/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

STI

SunTrust

$67.94

-0.41 (-0.60%)

SYF

Synchrony

$37.30

-0.76 (-2.00%)

CFG

Citizens Financial

$45.76

-0.08 (-0.17%)

RF

Regions Financial

$18.15

-0.21 (-1.14%)

KSU

Kansas City Southern

$111.50

0.69 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 20

    Apr

  • 20

    Jul

  • 19

    Oct

URGN

UroGen Pharma

$42.46

-0.8 (-1.85%)

19:12
01/18/18
01/18
19:12
01/18/18
19:12
Syndicate
UroGen Pharma 1.463M share Secondary priced at $41.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

ADT

ADT Inc.

19:10
01/18/18
01/18
19:10
01/18/18
19:10
Syndicate
ADT Inc. 105M share IPO priced at $17.00-19.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$279.14

-0.47 (-0.17%)

18:47
01/18/18
01/18
18:47
01/18/18
18:47
Periodicals
House Freedom Caucus to support bill preventing government shutdown, AP says 

Reference Link

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$279.14

-0.47 (-0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$55.35

-2.54 (-4.39%)

18:39
01/18/18
01/18
18:39
01/18/18
18:39
Periodicals
BNY Mellon to boost wages for 1,000 workers after tax reform, WSJ says »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 08

    Mar

TRNC

tronc

$19.23

0.22 (1.16%)

18:28
01/18/18
01/18
18:28
01/18/18
18:28
Periodicals
tronc to investigate LA Times' CEO Ross Levinsohn, Financial Times reports »

tronc has opened an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IBM

IBM

$169.12

0.47 (0.28%)

18:19
01/18/18
01/18
18:19
01/18/18
18:19
Hot Stocks
IBM's Schroeter says mainframe isn't going away »

IBM senior VP of Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ATR

AptarGroup

$87.24

0.4 (0.46%)

18:16
01/18/18
01/18
18:16
01/18/18
18:16
Hot Stocks
AptarGroup chairman King Harris to retire in May »

AptarGroup chairman of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 27

    Apr

  • 02

    May

  • 27

    Jul

  • 26

    Oct

FULT

Fulton Financial

$18.30

-0.25 (-1.35%)

18:12
01/18/18
01/18
18:12
01/18/18
18:12
Hot Stocks
Fulton Financial to raise its minimum wage to $12 per hour »

Fulton Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SNAP

Snap

$14.01

0.49 (3.62%)

18:03
01/18/18
01/18
18:03
01/18/18
18:03
Periodicals
Snap fires roughly two dozen employees, Cheddar reports »

Snap Inc. has laid off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 06

    Feb

  • 07

    Feb

PAVM

PAVmed

$2.54

-0.02 (-0.78%)

17:57
01/18/18
01/18
17:57
01/18/18
17:57
Syndicate
PAVmed files to sell common stock, no amount given »

Dawson James Securities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PODD

Insulet

$72.89

-0.02 (-0.03%)

, DXCM

Dexcom

$56.28

-0.04 (-0.07%)

17:51
01/18/18
01/18
17:51
01/18/18
17:51
Recommendations
Insulet, Dexcom, TNDM, Medtronic analyst commentary at Piper Jaffray »

Insulet is a favored…

PODD

Insulet

$72.89

-0.02 (-0.03%)

DXCM

Dexcom

$56.28

-0.04 (-0.07%)

TNDM

TNDM

MDT

Medtronic

$87.26

1.15 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

17:50
01/18/18
01/18
17:50
01/18/18
17:50
General news
Breaking General news story  »

Cleveland Federal Reserve…

IBM

IBM

$169.12

0.47 (0.28%)

17:39
01/18/18
01/18
17:39
01/18/18
17:39
Earnings
Breaking Earnings news story on IBM »

IBM sees FY18 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

TTD

Trade Desk

$48.36

-1.12 (-2.26%)

17:38
01/18/18
01/18
17:38
01/18/18
17:38
Initiation
Trade Desk initiated at Stifel »

Trade Desk initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$24.04

-0.52 (-2.12%)

, FB

Facebook

$179.80

2.2 (1.24%)

17:37
01/18/18
01/18
17:37
01/18/18
17:37
Hot Stocks
Snap user metrics being put into question by Mashable, Muddy Waters »

After the close, Mashable…

TWTR

Twitter

$24.04

-0.52 (-2.12%)

FB

Facebook

$179.80

2.2 (1.24%)

SNAP

Snap

$14.01

0.49 (3.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

TWTR

Twitter

$24.04

-0.52 (-2.12%)

17:37
01/18/18
01/18
17:37
01/18/18
17:37
Recommendations
Twitter analyst commentary at Stifel »

Twitter coverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

IBM

IBM

$169.12

0.47 (0.28%)

17:36
01/18/18
01/18
17:36
01/18/18
17:36
Hot Stocks
Breaking Hot Stocks news story on IBM »

IBM sees FY18 free cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IBM

IBM

$169.12

0.47 (0.28%)

17:36
01/18/18
01/18
17:36
01/18/18
17:36
Earnings
IBM sees Q1 EPS 17%-18% of $13.80 FY expectation, consensus $2.28 »

Says has momentum in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ZG

Zillow

$43.86

-0.49 (-1.10%)

, Z

Zillow

$43.97

-0.57 (-1.28%)

17:33
01/18/18
01/18
17:33
01/18/18
17:33
Downgrade
Zillow, Zillow rating change at Stifel »

Zillow resumed with a…

ZG

Zillow

$43.86

-0.49 (-1.10%)

Z

Zillow

$43.97

-0.57 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AXP

American Express

$99.86

-0.9 (-0.89%)

, HLT

Hilton

$83.95

-0.08 (-0.10%)

17:30
01/18/18
01/18
17:30
01/18/18
17:30
Hot Stocks
American Express 'excited' about co-brand partnership with Hilton and Marriott »

Says delinquencies will…

AXP

American Express

$99.86

-0.9 (-0.89%)

HLT

Hilton

$83.95

-0.08 (-0.10%)

MAR

Marriott

$141.13

-0.87 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 14

    Feb

  • 15

    Feb

  • 25

    Mar

APRN

Blue Apron

$3.20

0.04 (1.27%)

17:30
01/18/18
01/18
17:30
01/18/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Blue Apron »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.